Poll

A1C Target: When is a Less Stringent Goal Appropriate?

For which patients might a less stringent A1C goal -- of 8% -- be appropriate? A quiz, and the answer here.

A reasonable A1C goal for many nonpregnant adults is <7%. For some patients, however, a less stringent goal may be appropriate.
 

An A1C goal of 8% may be appropriate for which patient(s)?

A. An 80-year old woman with longstanding diabetes, cardiovascular disease, and prior multifocal stroke.
B. A 23-year-old with Down syndrome and poorly controlled T1 diabetes (diagnosed at age 12).
C. A 50-year-old with alcoholism, chronic pancreatitis, hepatic cirrhosis, portal hypertension, and esophageal varices.
D. B and C
E. All of the above
F. None of the above
Related Videos
Rahul Aggarwal, MD | Credit: LinkedIn
Brendon Neuen, MBBS, PhD | Credit: X.com
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Alexandra Louise Møller, MS, PhD | Credit: LinkedIn
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Optimizing Diabetes Therapies with New Classifications
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Related Content
Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center
October 21st 2024

Oral Semaglutide Reduces MACE Risk in People With Type 2 Diabetes and CVD

Victoria Johnson
Brian Hansen | Credit: Ascensia Diabetes Care
October 15th 2024

Diabetes Dialogue: What to Know About the Eversense 365 CGM, with Brian Hansen

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
HCPLive Endocrinology Month in Review September 2024 thumbnail
October 6th 2024

Endocrinology Month in Review: September 2024

Patrick Campbell
Taher Modarressi, MD | Credit: X.com
October 3rd 2024

Don't Miss a Beat: Putting Evidence-Based Cardiometabolic Therapies into Practice, with Taher Modarressi, MD

Muthiah Vaduganathan, MD, MPH Stephen Greene, MD
US FDA logo in black over a white background. | Credit: US Food and Drug Administration
September 18th 2024

FDA Clears Eversense 365, Marking First 1-Year CGM Option in Diabetes

Patrick Campbell
GLP-1 RA Linked to Lower Risk of Cirrhosis Development in Patients with MASLD
September 16th 2024

GLP-1 RA Linked to Lower Risk of Cirrhosis Development in Patients with MASLD

Chelsie Derman
© 2024 MJH Life Sciences

All rights reserved.